Introduction
Unnati Pharmax continues to expand its oncology portfolio with the launch of CAZANAT Tablets, a new-generation pharmaceutical product developed to meet evolving cancer treatment requirements. Manufactured under stringent quality systems, CAZANAT is designed to deliver consistency, safety, and reliability for oncology care when prescribed by qualified healthcare professionals.
This blog introduces the CAZANAT range, highlighting available strengths and key product features while supporting strong SEO visibility for Unnati Pharmax’s website.
About CAZANAT
CAZANAT tablets are formulated using high-quality active pharmaceutical ingredients and advanced manufacturing processes. The product is developed to ensure optimal stability, uniformity, and compliance with international pharmaceutical standards.
Unnati Pharmax focuses on precision formulation and robust quality control to support healthcare systems and global distribution partners.
CAZANAT Product Variants
CAZANAT 20 MG
CAZANAT 20 MG is formulated for treatment protocols that require lower-dose strength under medical supervision.
Key Features:
Accurate 20 mg dosage strength
Consistent tablet quality
GMP-compliant manufacturing
CAZANAT 40 MG
CAZANAT 40 MG is a mid-strength formulation designed to support a wide range of oncology treatment plans as prescribed.
Key Features:
Reliable formulation stability
Uniform drug distribution
Suitable for domestic and export markets
CAZANAT 60 MG
CAZANAT 60 MG is a higher-strength option developed for advanced treatment requirements under professional guidance.
Key Features:
Precise 60 mg strength
Stringent quality testing
Export-ready packaging options
Why Choose CAZANAT from Unnati Pharmax?
GMP-Certified Manufacturing Facilities
Multiple Strength Options: 20 mg, 40 mg, and 60 mg
Strict Quality Assurance & Control
Focus on Oncology Excellence
Global Supply Capability
Why Partner with Unnati Pharmax?
Unnati Pharmax is a trusted pharmaceutical company focused on delivering high-quality oncology and specialty medicines. Our commitment to regulatory compliance, innovation, and customer satisfaction makes us a preferred partner for distributors, exporters, and healthcare institutions.
Conclusion
The launch of CAZANAT 20 MG, CAZANAT 40 MG, and CAZANAT 60 MG strengthens Unnati Pharmax’s oncology product portfolio. Developed with quality, precision, and global standards in mind, CAZANAT tablets represent our ongoing commitment to advancing pharmaceutical care.
For distribution inquiries, third-party manufacturing opportunities, or product details, connect with Unnati Pharmax today.
